Skip to content
Next results · Q3 2027Projected

Feb 5, before the open

Fri, Feb 5, 2027in 80 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q3 2027 · Ends about Dec 31, 2026
10-Q window
Feb 3 – 12

Read against Q3 2026

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Net income
-$110.64M
Net income, change from a year earlier: Q2 2027 n/m, Q1 2027 n/m, Q4 2026 n/m, Q3 2026 n/m
EPS
-$0.61
EPS, change from a year earlier: Q2 2027 n/m, Q1 2027 n/m, Q3 2026 n/m, Q2 2026 n/m

Results day

Typical moveA typical move of 6.5% either way

Up after 6 of 12, down after 6.

The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: +35.3% after Q4 2026.

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

When it reports

Usual day
Varies
Session
before the open
After quarter end
37 to 50 days
10-Q filed
37 to 41 days
over its last 8
10-K filed
52 to 69 days
over its last 7

Based on 8 prior 10-Q filings.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR